Current and emerging therapy of dry eye disease. Part A: pharmacological modalities

References

• The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007 Apr;5(2);75–92.
   PubMed Web of Science ®Google Scholar
• The epidemiology of dry eye disease: report of the epidemiology subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007 Apr;5(2):93–107.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):1412–1419.
   PubMed Web of Science ®Google Scholar
• Mertzanis P, Abetz L, Rajagopalan K, et al. The relative burden of dry eye in patients’ lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci. 2005;46(1):46–50.
   PubMed Web of Science ®Google Scholar
• Miljanović B, Dana R, Sullivan DA, et al. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409–415.
   PubMed Web of Science ®Google Scholar
• Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30:379–387.
   PubMed Web of Science ®Google Scholar
• McDonald M, Patel DA, Keith MS, et al. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review. Ocul Surf. 2016 Apr;14(2):144–167.
   PubMed Web of Science ®Google Scholar
• Schaumberg DA, Dana R, Buring JE, et al. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009;127:763–768.
   PubMed Web of Science ®Google Scholar
• Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318–326.
   PubMed Web of Science ®Google Scholar
• Sy A, O’Brien KS, Liu MP, et al. Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED). BMC Ophthalmol. 2015;15:133.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Yamada M, Shigeyasu C. Annual direct cost of dry eye in Japan. Clin Ophthalmol. 2012;6:755–760.
   PubMedGoogle Scholar
• Brown MM, Brown GC, Brown HC, et al. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol. 2009;127:146–152.
   PubMedGoogle Scholar
• Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405–412.
   PubMedGoogle Scholar
• Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea. 2004;23(8):751–761.
   PubMed Web of Science ®Google Scholar
• Yamada M, Mizuno Y, Shigeyasu C. Impact of dry eye on work productivity. Clinicoecon Outcomes Res. 2012;4:307–312.
   PubMedGoogle Scholar
• Nassiri N, Djalilian AR, Hamrah P, et al. Dry eye. In: Holland EJ, Krachmer JH, Mannis MJ, editors. Cornea. 3rd ed. Missouri City (MO): Mosby Elsevier, Inc; 2010. p. 425–445.
   Google Scholar
• Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472–478.
   PubMed Web of Science ®Google Scholar
• Tong L, Chaurasia SS, Mehta JS, et al. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in singapore. Invest Ophthalmol Vis Sci. 2010;51:3449–3454.
   PubMed Web of Science ®Google Scholar
• Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt. 2009;29(6):573–583.
   PubMed Web of Science ®Google Scholar
• Kaercher T, Buchholz P, Kimmich F. Treatment of patients with keratoconjunctivitis sicca with Optive: results of a multicenter, open-label observational study in Germany. Clin Ophthalmol. 2009;3:33–39.
   PubMedGoogle Scholar
• Gensheimer WG, Kleinman DM, Gonzalez MO, et al. Novel formulation of glycerin 1% artificial tears extends tear film break-up time compared with Systane lubricant eye drops. J Ocul Pharmacol Ther. 2012;28(5):473–478.
   PubMed Web of Science ®Google Scholar
• Yokoi N, Takehisa Y, Kinoshita S. Correlation of tear lipid layer interference patterns with the diagnosis and severity of dry eye. Am J Ophthalmol. 1996;122:818–824.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Amako H, Yamamoto T, et al. Corneal-protective effects of an artificial tear containing sodium hyaluronate and castor oil on a porcine short-term dry eye model. J Vet Med Sci. 2014;76(9):1219–1224.
   PubMed Web of Science ®Google Scholar
• Rangarajan R, Kraybill B, Ogundele A, et al. Effects of a Hyaluronic Acid/Hydroxypropyl guar artificial tear solution on protection, recovery, and lubricity in models of corneal epithelium. J Ocul Pharmacol Ther. 2015;31(8):491–497.
   PubMed Web of Science ®Google Scholar
• Uchiyama E, Di Pascuale MA, Butovich IA, et al. Impact on ocular surface evaporation of an artificial tear solution containing hydroxypropyl guar. Eye Contact Lens. 2008;34(6):331–334.
   PubMed Web of Science ®Google Scholar
• Goto E, Shimazaki J, Monden Y, et al. Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. Ophthalmology. 2002;109(11):2030–2035.
   PubMed Web of Science ®Google Scholar
• Khanal S, Tomlinson A, Pearce EI, et al. Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye. Cornea. 2007 Feb;26(2):175–181.
   PubMed Web of Science ®Google Scholar
• Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm. 2002;53(3):263–280.
   PubMed Web of Science ®Google Scholar
• Charnock C. Are multidose over-the-counter artifical tears adequately preserved? Cornea. 2006;25(4):432–437.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Imperia PS, Botti RE, et al. An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents. Lens Eye Toxic Res. 1989;6(1–2):59–85.
   PubMedGoogle Scholar
• Moshirfar M, Pierson K, Hanamaikai K, et al. Artificial tears potpourri: a literature review. Clin Ophthalmol. 2014 Jul;31(8):1419–1433.
   Google Scholar
• Asbell PA. Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion. Curr Med Res Opin. 2006;22(11):2149–2157.
   PubMed Web of Science ®Google Scholar
• Kim MS, Choi CY, Kim JM, et al. Microbial contamination of multiply used preservative-free artificial tears packed in reclosable containers. Br J Ophthalmol. 2008;92(11):1518–1521.
   PubMed Web of Science ®Google Scholar
• Grene RB, Lankston P, Mordaunt J, et al. Unpreserved carboxymethylcellulose artificial tears evaluated in patients with keratoconjunctivitis sicca. Cornea. 1992;11(4):294–301.
   PubMed Web of Science ®Google Scholar
• Brodwall J, Alme G, Gedde-Dahl S, et al. A comparative study of polyacrylic acid (Viscotears) liquid gel versus polyvinylalcohol in the treatment of dry eyes. Acta Ophthalmol Scand. 1997;75(4):457–461.
   PubMedGoogle Scholar
• Tsubota K, Monden Y, Yagi Y, et al. New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery. Br J Ophthalmol. 1999;83(7):767–770.
   PubMed Web of Science ®Google Scholar
• Liu Z, Pflugfelder SC. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology. 1999;106(5):939–943.
   PubMed Web of Science ®Google Scholar
• Di Pascuale MA, Goto E, Tseng SCG. Sequential changes of lipid tear film after the instillation of a single drop of a new emulsion eye drop in dry eye patients. Ophthalmology. 2004;111(4):783–791.
   PubMed Web of Science ®Google Scholar
• Goto E, Dogru M, Fukagawa K, et al. Successful tear lipid layer treatment for refractory dry eye in office workers by low-dose lipid application on the full-length eyelid margin. Am J Ophthalmol. 2006;142(2):264–270.
   PubMed Web of Science ®Google Scholar
• Ousler GW, Michaelson C, Christensen MT. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea. 2007;26(8):949–952.
   PubMed Web of Science ®Google Scholar
• Prabhasawat P, Tesavibul N, Kasetsuwan N. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study. Br J Ophthalmol. 2007;91(1):47–50.
   PubMed Web of Science ®Google Scholar
• Tauber J. Efficacy, tolerability and comfort of a 0.3% hypromellose gel ophthalmic lubricant in the treatment of patients with moderate to severe dry eye syndrome. Curr Med Res Opin. 2007;23(11):2629–2636.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Murphy PJ, Boulton M. Carbomer and sodium hyaluronate eyedrops for moderate dry eye treatment. Optom Vis Sci. 2008;85(8):750–757.
   PubMed Web of Science ®Google Scholar
• Rolando M, Autori S, Badino F, et al. Protecting the ocular surface and improving the quality of life of dry eye patients: a study of the efficacy of an HP-guar containing ocular lubricant in a population of dry eye patients. J Ocul Pharmacol Ther. 2009;25(3):271–278.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Wang IJ, Ho JD, et al. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study. Clin Ther. 2010;32(1):44–52.
   PubMed Web of Science ®Google Scholar
• Waduthantri S, Yong SS, Tan CH, et al. Lubricant with gelling agent in treating dry eye in adult Chinese patients. Optom Vis Sci. 2012;89(11):1647–1653.
   PubMed Web of Science ®Google Scholar
• McCann LC, Tomlinson A, Pearce EI, et al. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea. 2012;31(1):1–5.
   PubMed Web of Science ®Google Scholar
• Jacobi C, Kruse FE, Cursiefen C. Prospective, randomized, controlled comparison of SYSTANE UD eye drops versus VISINE INTENSIV 1% EDO eye drops for the treatment of moderate dry eye. J Ocul Pharmacol Ther. 2012;28(6):598–603.
   PubMed Web of Science ®Google Scholar
• Comez AT, Tufan HA, Kocabiyik O, et al. Effects of lubricating agents with different osmolalities on tear osmolarity and other tear function tests in patients with dry eye. Curr Eye Res. 2013;38(11):1095–1103.
   PubMed Web of Science ®Google Scholar
• Sindt CW, Foulks GN. Efficacy of an artificial tear emulsion in patients with dry eye associated with meibomian gland dysfunction. Clin Ophthalmol. 2013;7:1713–1722.
   PubMedGoogle Scholar
• Lee HS, Ji YS, Yoon KC. Efficacy of hypotonic 0.18% sodium hyaluronate eye drops in patients with dry eye disease. Cornea. 2014;33(9):946–951.
   PubMed Web of Science ®Google Scholar
• Lekhanont K, Chuckpaiwong V, Vongthongsri A, et al. Effects of sodium hyaluronate on wavefront aberrations in dry eye patients. Optom Vis Sci. 2014;91(1):39–46.
   PubMed Web of Science ®Google Scholar
• Aguilar AJ, Marquez MI, Albera PA, et al. Effects of Systane((R)) Balance on noninvasive tear film break-up time in patients with lipid-deficient dry eye. Clin Ophthalmol. 2014;8:2365–2372.
   PubMedGoogle Scholar
• McDonald M, Schachet JL, Lievens CW, et al. Systane(R) ultra lubricant eye drops for treatment of contact lens-related dryness. Eye Contact Lens. 2014 Mar;40(2):106–110.
   PubMed Web of Science ®Google Scholar
• Kaercher T, Thelen U, Brief G, et al. A prospective, multicenter, noninterventional study of Optive Plus(®) in the treatment of patients with dry eye: the prolipid study. Clin Ophthalmol. 2014 Jun;17(8):1147–1155.
   Google Scholar
• Pinto-Bonilla JC, Del Olmo-Jimeno A, Llovet-Osuna F, et al. A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome. Ther Clin Risk Manag. 2015;11:595–603.
   PubMed Web of Science ®Google Scholar
• Ousler G 3rd, Devries DK, Karpecki PM, et al. An evaluation of Retaine ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye. Clin Ophthalmol. 2015;9:235–243.
   PubMed Web of Science ®Google Scholar
• Jee D, Park M, Lee HJ, et al. Comparison of treatment with preservative-free versus preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops after cataract surgery in patients with preexisting dry-eye syndrome. J Cataract Refract Surg. 2015;41(4):756–763.
   PubMed Web of Science ®Google Scholar
• Schmidl D, Schmetterer L, Witkowska KJ, et al. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. Cornea. 2015;34(4):421–426.
   PubMed Web of Science ®Google Scholar
• Fernandez KB, Epstein SP, Raynor GS, et al. Modulation of HLA-DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution. Clin Ophthalmol. 2015;9:1137–1145.
   PubMed Web of Science ®Google Scholar
• Kiss HJ, Nemeth J. Isotonic Glycerol and Sodium Hyaluronate containing artificial tear decreases conjunctivochalasis after one and three months: a self-controlled, unmasked study. Plos One. 2015;10(7):e0132656.
   PubMed Web of Science ®Google Scholar
• Simmons PA, Carlisle-Wilcox C, Chen R, et al. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial. Clin Ther. 2015;37(4):858–868.
   PubMed Web of Science ®Google Scholar
• Torkildsen G, Frisch S, Bai M, et al. Safety and comfort evaluation of a new formulation of Visine((R)) lubricant eye drops containing HydroBlend and GentlePur. Clin Ophthalmol. 2016;10:331–336.
   PubMed Web of Science ®Google Scholar
• Pinto-Fraga J, Lopez-De La Rosa A, Blazquez AF, et al. Efficacy and Safety of 0.2% Hyaluronic Acid in the management of dry eye disease. Eye Contact Lens. 2017;43(1):57–63.
   PubMed Web of Science ®Google Scholar
• Lopez-De La Rosa A, Pinto-Fraga J, Blazquez Arauzo F, et al. Safety and efficacy of an artificial tear containing 0.3% Hyaluronic Acid in the management of moderate-to-severe dry eye disease. Eye Contact Lens. 2016. DOI: 10.1097/ICL.0000000000000284. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Park Y, Song JS, Choi CY, et al. A randomized multicenter study comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the treatment of dry eye. J Ocul Pharmacol Ther. 2017;33(2):66–72.
   PubMed Web of Science ®Google Scholar
• Ngo W, Srinivasan S, Houtman D, et al. The relief of dry eye signs and symptoms using a combination of lubricants, lid hygiene and ocular nutraceuticals. J Optom. 2017;10(1):26–33.
   Google Scholar
• Chung SH, Lim SA, Tchach H. Efficacy and safety of carbomer-based lipid-containing artificial tear formulations in patients with dry eye syndrome. Cornea. 2016;35(2):181–186.
   PubMed Web of Science ®Google Scholar
• Brjesky VV, Maychuk YF, Petrayevsky AV, et al. Use of preservative-free hyaluronic acid (Hylabak(®)) for a range of patients with dry eye syndrome: experience in Russia. Clin Ophthalmol. 2014;8:1169–1177.
   PubMedGoogle Scholar
• Evangelista M, Koverech A, Messano M, et al. Comparison of three lubricant eye drop solutions in dry eye patients. Optom Vis Sci. 2011;88(12):1439–1444.
   PubMed Web of Science ®Google Scholar
• Benelli U. Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5:783–790.
   PubMedGoogle Scholar
• Calvão-Santos G, Borges C, Nunes S, et al. Efficacy of 3 different artificial tears for the treatment of dry eye in frequent computer users and/or contact lens users. Eur J Ophthalmol. 2011;21(5):538–544.
   PubMed Web of Science ®Google Scholar
• Springs CL. Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye. Adv Ther. 2010;27(10):681–690.
   PubMed Web of Science ®Google Scholar
• Sanchez MA, Torralbo-Jimenez P, Giron N, et al. Comparative analysis of carmellose 0.5% versus hyaluronate 0.15% in dry eye: a flow cytometric study. Cornea. 2010;29(2):167–171.
   PubMed Web of Science ®Google Scholar
• Sánchez MA, Arriola-Villalobos P, Torralbo-Jiménez P, et al. The effect of preservative-free HP-Guar on dry eye after phacoemulsification: a flow cytometric study. Eye (Lond). 2010;24(8):1331–1337.
   PubMed Web of Science ®Google Scholar
• Davitt WF, Bloomenstein M, Christensen M, et al. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation. J Ocul Pharmacol Ther. 2010;26(4):347–353.
   PubMed Web of Science ®Google Scholar
• Troiano P, Monaco G. Effect of hypotonic 0.4% hyaluronic acid drops in dry eye patients: a cross-over study. Cornea. 2008;27(10):1126–1130.
   PubMed Web of Science ®Google Scholar
• Christensen MT. Corneal staining reductions observed after treatment with Systane Lubricant Eye Drops. Adv Ther. 2008;25(11):1191–1199.
   PubMed Web of Science ®Google Scholar
• Foulks GN. Clinical evaluation of the efficacy of PEG/PG lubricant eye drops with gelling agent (HP-Guar) for the relief of the signs and symptoms of dry eye disease: a review. Drugs Today (Barc). 2007;43(12):887–896.
   PubMed Web of Science ®Google Scholar
• Simmons PA, Vehige JG. Clinical performance of a mid-viscosity artificial tear for dry eye treatment. Cornea. 2007;26(3):294–302.
   PubMed Web of Science ®Google Scholar
• Wang IJ, Lin IC, Hou YC, et al. A comparison of the effect of carbomer-, cellulose- and mineral oilbased artificial tear formulations. Eur J Ophthalmol. 2007;17(2):151–159.
   PubMed Web of Science ®Google Scholar
• Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86(2):181–184.
   PubMed Web of Science ®Google Scholar
• Papa V, Aragona P, Russo S, et al. Comparison of hypotonic and isotonic solutions containing sodium hyaluronate on the symptomatic treatment of dry eye patients. Ophthalmologica. 2001;215(2):124–127.
   PubMed Web of Science ®Google Scholar
• Lenton LM, Albietz JM. Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis. J Refract Surg. 1999;15(2 Suppl):S227–231.
   PubMed Web of Science ®Google Scholar
• Laflamme MY, Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can J Ophthalmol. 1988;23(4):174–176.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Cochener B, Pisella PJ, et al. Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease. Eur J Ophthalmol. 2012;22(5):751–761.
   PubMed Web of Science ®Google Scholar
• Cohen S, Martin A, Sall K. Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose. Clin Ophthalmol. 2014;8:157–164.
   PubMedGoogle Scholar
• Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003 Oct;136(4):593–602.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004 Sep;138(3):444–457.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014;40(5):289–296.
   PubMed Web of Science ®Google Scholar
• Jung HH, Ji YS, Sung MS, et al. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with sjögren’s syndrome. Chonnam Med J. 2015;51(1):26–32.
   PubMedGoogle Scholar
• Boynton GE, Raoof D, Niziol LM, et al. Prospective randomized trial comparing efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation. Cornea. 2015;34(7):725–732.
   PubMed Web of Science ®Google Scholar
• Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999;106(4):811–816.
   PubMed Web of Science ®Google Scholar
• Byun YJ, Kim TI, Kwon SM, et al. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. Cornea. 2012;31(5):509–513.
   PubMed Web of Science ®Google Scholar
• Pinto-Fraga J, López-Miguel A, González-García MJ, et al. Topical fluorometolone protects the lacrimal functional unit of dry eye patients from desiccating stress. A randomized clinical trial. Ophthalmology. 2016;123:141–153.
   PubMed Web of Science ®Google Scholar
• Moore QL, De Paiva CS, Pflugfelder SC. Effects of dry eye therapies on environmentally induced ocular surface disease. Am J Ophthalmol. 2015;160(1):135–142.e1.
   PubMed Web of Science ®Google Scholar
• Aragona P, Spinella R, Rania L, et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome. Eur J Ophthalmol. 2013;23(3):368–376.
   PubMed Web of Science ®Google Scholar
• Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol. 2011;5:633–643.
   PubMedGoogle Scholar
• Lee HK, Ryu IH, Seo KY, et al. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology. 2006;113(2):198–205.
   PubMed Web of Science ®Google Scholar
• Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006;7(8):675–678.
   PubMedGoogle Scholar
• Lee JH, Min K, Kim SK, et al. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone. Yonsei Med J. 2014;55(1):203–208.
   PubMed Web of Science ®Google Scholar
• Jonisch J, Steiner A, Udell IJ. Preservative-free low-dose dexamethasone for the treatment of chronic ocular surface disease refractory to standard therapy. Cornea. 2010;29(7):723–726.
   PubMed Web of Science ®Google Scholar
• Hong S, Kim T, Chung SH, et al. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren’s syndrome. J Ocul Pharmacol Ther. 2007;23(1):78–82.
   PubMed Web of Science ®Google Scholar
• Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993 Jul;12(4):315–323.
   PubMed Web of Science ®Google Scholar
• Hom MM. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. Eye Contact Lens. 2006 Mar;32(2):109–111.
   PubMedGoogle Scholar
• Salib GM, McDonald MB, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg. 2006;32(5):772–778.
   PubMed Web of Science ®Google Scholar
• Willen CM, McGwin G, Liu B, et al. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. Eye Contact Lens. 2008;34(1):43–45.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Burrell K, Gaddie IB, et al. Efficacy of a new prescription-only medical food supplement in alleviating signs and symptoms of dry eye, with or without concomitant cyclosporine A. Clin Ophthalmol. 2011;5:1201–1206.
   PubMedGoogle Scholar
• Lee HS, Jang JY, Lee SH, et al. Clinical effectiveness of topical cyclosporine a 0.05% after laser epithelial keratomileusis. Cornea. 2013;32(7):e150–155.
   PubMed Web of Science ®Google Scholar
• Chen M, Gong L, Sun X, et al. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial. J Ocul Pharmacol Ther. 2010;26(4):361–366.
   PubMed Web of Science ®Google Scholar
• Altiparmak UE, Acar DE, Ozer PA, et al. Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients. Eye (Lond). 2010;24(6):1044–1050.
   PubMed Web of Science ®Google Scholar
• Rao SN. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. J Ocul Pharmacol Ther. 2010;26(2):157–164.
   PubMed Web of Science ®Google Scholar
• Guzey M, Karaman SK, Satici A, et al. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye. Clin Exp Ophthalmol. 2009;37(6):541–549.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, De Paiva CS, Villarreal AL, et al. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor beta 2 production. Cornea. 2008;27(1):64–69.
   PubMed Web of Science ®Google Scholar
• Hardten DR, Brown MJ, Pham-Vang S. Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease. Curr Med Res Opin. 2007;23(9):2083–2091.
   PubMed Web of Science ®Google Scholar
• Rao SN, Rao RD. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease. Cornea. 2006;25(6):674–678.
   PubMed Web of Science ®Google Scholar
• Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114(1):76–79.
   PubMed Web of Science ®Google Scholar
• Sall KN, Cohen SM, Christensen MT, et al. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens. 2006;32(1):21–26.
   PubMedGoogle Scholar
• Stonecipher K, Perry HD, Gross RH, et al. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin. 2005;21(7):1057–1063.
   PubMed Web of Science ®Google Scholar
• Hartstein I, Khwarg S, Przydryga J. An open-label evaluation of HP-Guar gellable lubricant eye drops for the improvement of dry eye signs and symptoms in a moderate dry eye adult population. Curr Med Res Opin. 2005;21(2):255–260.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107(4):631–639.
   PubMed Web of Science ®Google Scholar
• Toda I, Shinozaki N, Tsubota K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren’s syndrome. Cornea. 1996;15(2):120–128.
   PubMed Web of Science ®Google Scholar
• Wang L, Chen X, Hao J, et al. Proper balance of omega-3 and omega-6 fatty acid supplements with topical cyclosporine attenuated contact lens-related dry eye syndrome. Inflammopharmacology. 2016;24(6):389–396.
   PubMed Web of Science ®Google Scholar
• Kang H, Cha KH, Cho W, et al. Cyclosporine Amicellar delivery system for dry eyes. Int J Nanomedicine. 2016;11:2921–2933.
   PubMed Web of Science ®Google Scholar
• Stonecipher KG, Torkildsen GL, Ousler GW 3rd, et al. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol. 2016;10:887–895.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–296.
   PubMed Web of Science ®Google Scholar
• Torricelli AA, Santhiago MR, Wilson SE. Topical cyclosporine a treatment in corneal refractive surgery and patients with dry eye. J Refract Surg. 2014;30(8):558–564.
   PubMed Web of Science ®Google Scholar
• Devecı H, Kobak S. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren’s syndrome. Int Ophthalmol. 2014;34(5):1043–1048.
   PubMed Web of Science ®Google Scholar
• Chung YW, Oh TH, Chung SK. The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol. 2013;27(3):167–171.
   PubMedGoogle Scholar
• Prabhasawat P, Tesavibul N, Karnchanachetanee C, et al. Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye. J Ocul Pharmacol Ther. 2013;29(3):372–377.
   PubMed Web of Science ®Google Scholar
• Mah F, Milner M, Yiu S, et al. PERSIST: physician’s evaluation of Restasis(®) Satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clin Ophthalmol. 2012;6:1971–1976.
   PubMedGoogle Scholar
• Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea. 2012;31(12):1386–1393.
   PubMed Web of Science ®Google Scholar
• Kara N, Altinkaynak H, Goker Y, et al. Evaluation of corneal morphologic and functional parameters after use of topical cyclosporine-a 0.05% in dry eye. J Ocul Pharmacol Ther. 2012;28(6):593–597.
   PubMed Web of Science ®Google Scholar
• Byun YS, Rho CR, Cho K, et al. Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study. Korean J Ophthalmol. 2011;25(6):369–374.
   PubMedGoogle Scholar
• Rao SN. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal. J Ocul Pharmacol Ther. 2011;27(6):603–609.
   PubMed Web of Science ®Google Scholar
• Demiryay E, Yaylali V, Cetin EN, et al. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome. Eye Contact Lens. 2011;37(5):312–315.
   PubMed Web of Science ®Google Scholar
• Su MY, Perry HD, Barsam A, et al. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy. Cornea. 2011;30(10):1098–1104.
   PubMed Web of Science ®Google Scholar
• Sahli E, Hoşal BM, Zilelioğlu G, et al. The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye. Cornea. 2010;29(12):1412–1416.
   PubMed Web of Science ®Google Scholar
• Malta JB, Soong HK, Shtein RM, et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea. 2010;29(12):1392–1396.
   PubMed Web of Science ®Google Scholar
• Gürdal C, Genç I, Saraç O, et al. Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression. Curr Eye Res. 2010;35(9):771–777.
   PubMed Web of Science ®Google Scholar
• Baiza-Durán L, Medrano-Palafox J, Hernández-Quintela E, et al. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol. 2010;94(10):1312–1315.
   PubMed Web of Science ®Google Scholar
• Kurt RA, YalçIndag N, Atilla H, et al. Topical cyclosporine-A in dry eye associated with chronic graft versus host disease. Ann Ophthalmol (Skokie). 2009;41(3–4):166–169.
   PubMedGoogle Scholar
• YüKsel B, Bozdağ B, Acar M, et al. Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients. Eur J Ophthalmol. 2010;20(4):675–679.
   PubMed Web of Science ®Google Scholar
• Toker E, AsfuroğLu E. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Cornea. 2010;29(2):133–140.
   PubMed Web of Science ®Google Scholar
• Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28(10):1091–1096.
   PubMed Web of Science ®Google Scholar
• Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046–1050.
   PubMedGoogle Scholar
• Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009;147(2):206–213.e3.
   PubMed Web of Science ®Google Scholar
• Moon JW, Lee HJ, Shin KC, et al. Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in patients with dry eye. Korean J Ophthalmol. 2007;21(4):189–194.
   PubMedGoogle Scholar
• Wang Y, Ogawa Y, Dogru M, et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2008;41(3):293–302.
   PubMed Web of Science ®Google Scholar
• Jain AK, Sukhija J, Dwedi S, et al. Effect of topical cyclosporine on tear functions in tear-deficient dry eyes. Ann Ophthalmol (Skokie). 2007;39(1):19–25.
   PubMedGoogle Scholar
• Cordero-Coma M, Anzaar F, Sobrin L, et al. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Ocul Immunol Inflamm. 2007;15(2):99–104.
   PubMed Web of Science ®Google Scholar
• Lelli GJ Jr, Musch DC, Gupta A, et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea. 2006;25(6):635–638.
   PubMed Web of Science ®Google Scholar
• Fiscella RG, Lee JT, Walt JG, et al. Utilization characteristics of topical cycolsporine and punctal plugs in a managed care database. Am J Manag Care. 2008;14(3 Suppl):S107–112.
   PubMedGoogle Scholar
• Barber LD, Pflugfelder SC, Tauber J, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790–1794.
   PubMed Web of Science ®Google Scholar
• Perry HD, Donnenfeld ED. Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother. 2004;5(10):2099–2107.
   PubMed Web of Science ®Google Scholar
• Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107(5):967–974.
   PubMed Web of Science ®Google Scholar
• GüNdüZ K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome. Acta Ophthalmol (Copenh). 1994;72(4):438–442.
   PubMed Web of Science ®Google Scholar
• Fullard RJ, Kaswan RM, Bounous DI, et al. Tear protein profiles vs. clinical characteristics of untreated andcyclosporine-treated canine KCS. J Am Optom Assoc. 1995;66(7):397–404.
   PubMedGoogle Scholar
• Zhou XQ, Wei RL. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis. Cornea. 2014;33(7):760–767.
   PubMed Web of Science ®Google Scholar
• Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% Cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf. 2015;13(3):213–225.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Mantelli F, Lambiase A, et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol. 2014;98(8):1016–1022.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea. 2001;20(4):430–434.
   PubMed Web of Science ®Google Scholar
• Tam PM, Young AL, Cheng LL, et al. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transplant. 2010;45(5):957–958.
   PubMed Web of Science ®Google Scholar
• Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea. 2012;31(8):945–949.
   PubMed Web of Science ®Google Scholar
• Sanz-Marco E, Udaondo P, García-Delpech S, et al. Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops. J Ocul Pharmacol Ther. 2013;29(8):776–783.
   PubMed Web of Science ®Google Scholar
• Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, et al. Treatment of Sjögren’s syndrome dry eye using 0.03% tacrolimus eye drop: prospective double-blind randomized study. Cont Lens Anterior Eye. 2015;38(5):373–378.
   PubMed Web of Science ®Google Scholar
• Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153(6):1050–1060.e1.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. OPUS-1 Study Group. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475–483.
   PubMed Web of Science ®Google Scholar
• Tauber J, Karpecki P, Latkany R, et al. OPUS-2 Investigators. Lifitegrast Ophthalmic Solution 5.0% versus placebo for treatment of dry eye disease: results of the Randomized Phase III OPUS-2 Study. Ophthalmology. 2015;122(12):2423–2431.
   PubMed Web of Science ®Google Scholar
• Berdy GJ, Abelson MB, Smith LM, et al. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol. 1992;110:528–532.
   PubMed Web of Science ®Google Scholar
• Huang JF, Yafawi R, Zhang M, et al. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology. 2012;119(7):e43–50.
   PubMed Web of Science ®Google Scholar
• Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology. 2012;119(7):1328–1335.
   PubMed Web of Science ®Google Scholar
• Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005;19(4):258–263.
   PubMedGoogle Scholar
• Seitsalo H, Niemelä RK, Marinescu-Gava M, et al. Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjögren’s syndrome: a randomized, double-blind, placebo controlled cross-over study. J Negat Results Biomed. 2007;6:11.
   PubMedGoogle Scholar
• Souchier M, Joffre C, Grégoire S, et al. Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment. Br J Ophthalmol. 2008;92(6):819–822.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Shigeno Y, Sato EA, et al. The evaluation of the treatment response in obstructive meibomian gland disease by in vivo laser confocal microscopy. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):821–829.
   PubMed Web of Science ®Google Scholar
• Lee H, Min K, Kim EK, et al. Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction. Am J Ophthalmol. 2012;154(6):949–957.e1.
   PubMed Web of Science ®Google Scholar
• Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea. 2013;32(1):44–53.
   PubMed Web of Science ®Google Scholar
• Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea. 2010;29(7):781–788.
   PubMed Web of Science ®Google Scholar
• Nichols JJ, Bickle KM, Zink RC, et al. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye. Eye Contact Lens. 2012 Mar;38(2):73–79.
   PubMed Web of Science ®Google Scholar
• Kashkouli MB, Fazel AJ, Kiavash V, et al. Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial. Br J Ophthalmol. 2015;99(2):199–204.
   PubMed Web of Science ®Google Scholar
• Tseng SC. Topical retinoid treatment for dry eye disorders. Trans Ophthalmol Soc U K. 1985;104:489–495.
   PubMedGoogle Scholar
• Tseng SC, Maumenee AE, Stark WJ, et al. Topical retinoid treatment for various dry-eye disorders. Ophthalmology. 1985;92:717–727.
   PubMed Web of Science ®Google Scholar
• Selek H, Unlü N, Orhan M, et al. Evaluation of retinoic acid ophthalmic emulsion in dry eye. Eur J Ophthalmol. 2000;10(2):121–127.
   PubMed Web of Science ®Google Scholar
• Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009;147(2):206–213.e3.
   PubMed Web of Science ®Google Scholar
• Soong HK, Martin NF, Wagoner MD, et al. Topical retinoid therapy for squamous metaplasia of various ocular surface disorders. A multicenter, placebo controlled double-masked study. Ophthalmology. 1988;95:1442–1446.
   PubMed Web of Science ®Google Scholar
• Gilbard JP, Huang AJ, Belldegrun R, et al. Open-label crossover study of vitamin A ointment as a treatment for keratoconjunctivitis sicca. Ophthalmology. 1989;96:244–246.
   PubMed Web of Science ®Google Scholar
• Larmo PS, Jarvinen RL, Setala NL, et al. Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye. J Nutr. 2010;140:1462–1468.
   PubMed Web of Science ®Google Scholar
• Brignole-Baudouin F, Baudouin C, Aragona P, et al. A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmol. 2011;89:e591–597.
   PubMed Web of Science ®Google Scholar
• Galbis-Estrada C, Pinazo-Durán MD, Cantú-Dibildox J, et al. Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. Clin Interv Aging. 2013;8:711–719.
   PubMed Web of Science ®Google Scholar
• Pinazo-Durán MD, Galbis-Estrada C, Pons-Vázquez S, et al. Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders. Clin Interv Aging. 2013;8:139–148.
   PubMed Web of Science ®Google Scholar
• Oleñik A, Jiménez-Alfaro I, Alejandre-Alba N, et al. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clin Interv Aging. 2013;8:1133–1138.
   PubMed Web of Science ®Google Scholar
• Oleñik A. Effectiveness and tolerability of dietary supplementation with a combination of omega-3 polyunsaturated fatty acids and antioxidants in the treatment of dry eye symptoms: results of a prospective study. Clin Ophthalmol. 2014;8:169–176.
   PubMedGoogle Scholar
• Galbis-Estrada C, Pinazo-Durán MD, Martínez-Castillo S, et al. A metabolomic approach to dry eye disorders. The role of oral supplements with antioxidants and omega 3 fatty acids. Mol Vis. 2015;21:555–567. eCollection 2015
   PubMed Web of Science ®Google Scholar
• Gatell-Tortajada J. Oral supplementation with a nutraceutical formulation containing omega-3 fatty acids, vitamins, minerals, and antioxidants in a large series of patients with dry eye symptoms: results of a prospective study. Clin Interv Aging. 2016;11:571–578.
   PubMedGoogle Scholar
• Tellez-Vazquez J. Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. Clin Ophthalmol. 2016;10:617–626.
   PubMed Web of Science ®Google Scholar
• Patel S, Plaskow J, Ferrier C. The influence of vitamins and trace element supplements on the stability of the pre-corneal tear film. Acta Ophthalmol (Copenh). 1993;71(6):825–829.
   PubMed Web of Science ®Google Scholar
• Blades KJ, Patel S, Aidoo KE. Oral antioxidant therapy for marginal dry eye. Eur J Clin Nutr. 2001;55(7):589–597.
   PubMed Web of Science ®Google Scholar
• Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial. Eur J Ophthalmol. 2009;19(3):337–342.
   PubMed Web of Science ®Google Scholar
• Brzheskiy VV, Efimova EL, Vorontsova TN, et al. Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of visomitin eye drops in patients with dry eye syndrome. Adv Ther. 2015;32(12):1263–1279.
   PubMed Web of Science ®Google Scholar
• Choi W, Kim JC, Kim WS, et al. Clinical effect of antioxidant glasses containing extracts of medicinal plants in patients with dry eye disease: a multi-center, prospective, randomized, double-blind, placebo-controlled trial. Plos One. 2015;10(10):e0139761.
   PubMed Web of Science ®Google Scholar
• Huang JY, Yeh PT, Hou YC. A randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye syndrome. Clin Ophthalmol. 2016;10:813–820.
   PubMed Web of Science ®Google Scholar
• Miljanovic B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr. 2005;82:887–893.
   PubMed Web of Science ®Google Scholar
• Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336–356.
   PubMedGoogle Scholar
• Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea. 2011;30:308–314.
   PubMed Web of Science ®Google Scholar
• Bhargava R, Kumar P, Kumar M, et al. A randomized controlled trial of omega-3 fatty acids in dry eye syndrome. Int J Ophthalmol. 2013;6:811–816.
   PubMed Web of Science ®Google Scholar
• Kangari H, Eftekhari MH, Sardari S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology. 2013;120:2191–2196.
   PubMed Web of Science ®Google Scholar
• Olen˜ik A, Jime´nez-Alfaro I, Alejandre-Alba N, et al. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clin Interv Aging. 2013;8:1133–1138.
   PubMed Web of Science ®Google Scholar
• Kawakita T, Kawabata F, Tsuji T, et al. Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial. Biomed Res. 2013;34:215–220.
   PubMed Web of Science ®Google Scholar
• Korb DR, Blackie CA, Finnemore VM, et al. Effect of using a combination of lid wipes, eye drops, and omega-3 supplements on meibomian gland functionality in patients with lipid deficient/evaporative dry eye. Cornea. 2015;34(4):407–412.
   PubMed Web of Science ®Google Scholar
• Bhargava R, Kumar P. Oral omega-3 fatty acid treatment for dry eye in contact lens wearers. Cornea. 2015;34(4):413–420.
   PubMed Web of Science ®Google Scholar
• Bhargava R, Kumar P, Phogat H, et al. Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye. Cont Lens Anterior Eye. 2015;38(3):206–210.
   PubMed Web of Science ®Google Scholar
• Bhargava R, Chandra M, Bansal U, et al. A randomized controlled trial of Omega 3 Fatty Acids in rosacea patients with dry eye symptoms. Curr Eye Res. 2016;41(10):1274–1280.
   PubMed Web of Science ®Google Scholar
• Bhargava R, Kumar P, Arora Y. Short-term Omega 3 Fatty Acids treatment for dry eye in young and middle-aged visual display terminal users. Eye Contact Lens. 2016;42(4):231–236.
   PubMed Web of Science ®Google Scholar
• Galor A, Gardener H, Pouyeh B, et al. Effect of a Mediterranean dietary pattern and vitamin D levels on Dry Eye syndrome. Cornea. 2014;33(5):437–441.
   PubMed Web of Science ®Google Scholar
• Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies. Med Sci Monit. 2014;20:1583–1589.
   PubMed Web of Science ®Google Scholar
• Aragona P, Bucolo C, Spinella R, et al. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren’s syndrome patients. Invest Ophthalmol Vis Sci. 2005;46:4474–4479.
   PubMed Web of Science ®Google Scholar
• Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye. 2008;31:141–146.
   PubMedGoogle Scholar
• Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 2003;22(2):97–101.
   PubMed Web of Science ®Google Scholar
• Creuzot C, Passemard M, Viau S, et al. Improvement of dry eye symptoms with polyunsaturated fatty acids. J Fr Ophtalmol. 2006;29:868–873.
   PubMed Web of Science ®Google Scholar
• Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gamma linolenic acid on meibomian gland dysfunction. Cornea. 2007;26(3):260–264.
   PubMed Web of Science ®Google Scholar
• Creuzot-Garcher C, Baudouin C, Labetoulle M, et al. [Efficacy assessment of Nutrilarm®, a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome]. J Fr Ophtalmol. 2011;34(7):448–455.
   PubMed Web of Science ®Google Scholar
• Sheppard JD Jr., Singh R, McClellan AJ, et al. Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. Cornea. 2013;32(10):1297–1304.
   PubMed Web of Science ®Google Scholar
• Aragona P, Rania L, Roszkowska AM, et al. Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome. Acta Ophthalmol. 2013;91(6):e437–444.
   PubMed Web of Science ®Google Scholar
• Worda C, Nepp J, Huber JC, et al. Treatment of keratoconjunctivitis sicca with topical androgen. Maturitas. 2001;37(3):209–212.
   PubMed Web of Science ®Google Scholar
• Nanavaty MA, Long M, Malhotra R. Transdermal androgen patches in evaporative dry eye syndrome with androgen deficiency: a pilot study. Br J Ophthalmol. 2014;98(4):567–569.
   PubMed Web of Science ®Google Scholar
• Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000;85(12):4874–4882.
   PubMed Web of Science ®Google Scholar
• Akramian J, Wedrich A, Nepp J, et al. Estrogen therapy in keratoconjunctivitis sicca. Adv Exp Med Biol. 1998;438:1005–1009.
   PubMed Web of Science ®Google Scholar
• Sator MO, Joura EA, Golaszewski T, et al. Treatment of menopausal keratoconjunctivitis sicca with topical oestradiol. Br J Obstet Gynaecol. 1998;105(1):100–102.
   PubMedGoogle Scholar
• Pelit A, Bağiş T, Kayaselçuk F, et al. Tear function tests and conjunctival impression cytology before and after hormone replacement therapy in postmenopausal women. Eur J Ophthalmol. 2003;13(4):337–342.
   PubMed Web of Science ®Google Scholar
• Evans V, Millar TJ, Eden JA, et al. Menopause, hormone replacement therapy and tear function. Adv Exp Med Biol. 2002;506(Pt B):1029–1033.
   PubMed Web of Science ®Google Scholar
• Scott G, Yiu SC, Wasilewski D, et al. Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. Am J Ophthalmol. 2005;139(6):1109–1110.
   PubMed Web of Science ®Google Scholar
• Feng Y, Feng G, Peng S, et al. The effects of hormone replacement therapy on dry eye syndromes evaluated by Schirmer test depend on patient age. Cont Lens Anterior Eye. 2016;39(2):124–127.
   PubMed Web of Science ®Google Scholar
• Barney NP. Can hormone replacement therapy cause dry eye? Arch Ophthalmol. 2002;120(5):641–642.
   PubMedGoogle Scholar
• Mathers WD, Dolney AM, Kraemer D. The effect of hormone replacement therapy on the symptoms and physiologic parameters of dry eye. Adv Exp Med Biol. 2002;506(Pt B):1017–1022.
   PubMed Web of Science ®Google Scholar
• Uncu G, Avci R, Uncu Y, et al. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol Endocrinol. 2006;22(9):501–505.
   PubMed Web of Science ®Google Scholar
• Erdem U, Ozdegirmenci O, Sobaci E, et al. Dry eye in post-menopausal women using hormone replacement therapy. Maturitas. 2007;56(3):257–262.
   PubMed Web of Science ®Google Scholar
• Piwkumsribonruang N, Somboonporn W, Luanratanakorn P, et al. Effectiveness of hormone therapy for treating dry eye syndrome in postmenopausal women: a randomized trial. J Med Assoc Thai. 2010;93(6):647–652.
   PubMedGoogle Scholar
• Al-Awlaqi A, Hammadeh M. Examining the relationship between hormone therapy and dry-eye syndrome in postmenopausal women: a cross-sectional comparison study. Menopause. 2016;23(5):550–555.
   PubMed Web of Science ®Google Scholar
• Akyol-Salman I, Azizi S, Mumcu U, et al. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther. 2010;26(4):329–333.
   PubMed Web of Science ®Google Scholar
• Akyol-Salman I, Azizi S, Mumcu UY, et al. Comparison of the efficacy of topical N-acetyl-cysteine and a topical steroid-antibiotic combination therapy in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther. 2012;28(1):49–52.
   PubMed Web of Science ®Google Scholar
• Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999;159(2):174–181.
   PubMedGoogle Scholar
• Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46(3):748–754.
   PubMed Web of Science ®Google Scholar
• Bhamra J, Wong J, Gohill J. Oral pilocarpine for the treatment of keratoconjunctivitis sicca with central corneal irregularity. J Cataract Refract Surg. 2003;29(11):2236–2238.
   PubMed Web of Science ®Google Scholar
• Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome: a randomised 12 week controlled study. Ann Rheum Dis. 2003;62(12):1204–1207.
   PubMed Web of Science ®Google Scholar
• Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in Sjögren’s Syndrome Patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol. 2004;10(4):169–177.
   PubMed Web of Science ®Google Scholar
• Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138(1):6–17.
   PubMed Web of Science ®Google Scholar
• Aragona P, Di Pietro R, Spinella R, et al. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren’s syndrome. Br J Ophthalmol. 2006;90(2):166–170.
   PubMed Web of Science ®Google Scholar
• Kawakita T, Shimmura S, Tsubota K. Effect of oral pilocarpine in treating severe dry eye in patients with Sjögren Syndrome. Asia Pac J Ophthalmol (Phila). 2015;4(2):101–105.
   PubMedGoogle Scholar
• Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23(8):784–792.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Nakanishi M, Ishii R, et al. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond). 2012;26(10):1363–1368.
   PubMed Web of Science ®Google Scholar
• Takamura E, Tsubota K, Watanabe H, et al. Diquafosol Ophthalmic Solution Phase 3 Study Group. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96(10):1310–1315.
   PubMed Web of Science ®Google Scholar
• Shimazaki-Den S, Iseda H, Dogru M, et al. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea. 2013;32(8):1120–1125.
   PubMed Web of Science ®Google Scholar
• Mori Y, Nejima R, Masuda A, et al. Effect of diquafosol tetrasodium eye drop for persistent dry eye after laser in situ keratomileusis. Cornea. 2014;33(7):659–662.
   PubMed Web of Science ®Google Scholar
• Toda I, Ide T, Fukumoto T, et al. Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis. Am J Ophthalmol. 2014;157(3):616–622.e1.
   PubMed Web of Science ®Google Scholar
• Yang JM, Choi W, Kim N, et al. Comparison of topical cyclosporine and diquafosol treatment in dry eye. Optom Vis Sci. 2015;92(9):e296–302.
   PubMed Web of Science ®Google Scholar
• Yokoi N, Sonomura Y, Kato H, et al. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjogren’s syndrome. Eye (Lond). 2015;29(9):1204–1212.
   PubMed Web of Science ®Google Scholar
• Gong L, Sun X, Ma Z, et al. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol. 2015;99(7):903–908.
   PubMed Web of Science ®Google Scholar
• Jeon HS, Hyon JY. The efficacy of diquafosol ophthalmic solution in Non-Sjögren and Sjögren Syndrome dry eye patients unresponsive to artificial tear. J Ocul Pharmacol Ther. 2016;32(7):463–468.
   PubMed Web of Science ®Google Scholar
• Baek J, Doh SH, Chung SK. The effect of topical Diquafosol Tetrasodium 3% on dry eye after cataract surgery. Curr Eye Res. 2016;41(10):1281–1285.
   PubMed Web of Science ®Google Scholar
• Miyake H, Kawano Y, Tanaka H, et al. Tear volume estimation using a modified Schirmer test: a randomized, multicenter, double-blind trial comparing 3% diquafosol ophthalmic solution and artificial tears in dry eye patients. Clin Ophthalmol. 2016;10:879–886.
   PubMed Web of Science ®Google Scholar
• Shigeyasu C, Yamada M, Akune Y, et al. Diquafosol for Soft Contact Lens Dryness: clinical evaluation and tear analysis. Optom Vis Sci. 2016;93(8):973–978.
   PubMed Web of Science ®Google Scholar
• Lee JH, Song IS, Kim KL, et al. Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery. J Ophthalmol. 2016;2016:8150757.
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide Ophthalmic Suspension Phase II Study Group. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology. 2012;119(12):2471–2478.
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Oshiden K, Awamura S, et al. Rebamipide Ophthalmic Suspension Phase 3 Study Group. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology. 2013;120(6):1158–1165.
   PubMed Web of Science ®Google Scholar
• Koh S, Inoue Y, Sugmimoto T, et al. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013;32(9):1219–1223.
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Awamura S, Nakamichi N, et al. Rebamipide Ophthalmic Suspension Long-term Study Group. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol. 2014;157(3):576–583.e1.
   PubMed Web of Science ®Google Scholar
• Arimoto A, Kitagawa K, Mita N, et al. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions. Cornea. 2014;33(8):806–811.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Fujita M, Yamada Y, et al. Improvements in Signs and Symptoms of Dry Eye after Instillation of 2% Rebamipide. J Nippon Med Sch. 2015;82(5):229–236.
   PubMed Web of Science ®Google Scholar
• Ueda K, Matsumiya W, Otsuka K, et al. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol. 2015;15:58.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjögren’s syndrome. Br J Ophthalmol. 1999;83(4):390–395.
   PubMed Web of Science ®Google Scholar
• Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802–806.
   PubMed Web of Science ®Google Scholar
• Goto E, Shimmura S, Shimazaki J, et al. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001;20:807–810.
   PubMed Web of Science ®Google Scholar
• Takamura E, Shinozaki K, Hata H, et al. Efficacy of autologous serum treatment in patients with severe dry eye. Adv Exp Med Biol. 2002;506(Pt B):1247–1250.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Oguchi Y. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2003;31(7):579–583.
   PubMed Web of Science ®Google Scholar
• Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004;88:647–652.
   PubMed Web of Science ®Google Scholar
• Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol. 2005;139(2):242–246.
   PubMed Web of Science ®Google Scholar
• Noda-Tsuruya T, Asano-Kato N, Toda I, et al. Autologous serum eye drops for dry eye after LASIK. J Refract Surg. 2006;22:61–66.
   PubMed Web of Science ®Google Scholar
• Lee GA, Chen SX. Autologous serum in the management of recalcitrant dry eye syndrome. Clin Exp Ophthalmol. 2008;36:119–122.
   PubMed Web of Science ®Google Scholar
• López-García JS, Rivas L, García-Lozano I, et al. Autologous serum eyedrops in the treatment of aniridic keratopathy. Ophthalmology. 2008;115(2):262–267.
   PubMed Web of Science ®Google Scholar
• Urzua CA, Vasquez DH, Huidobro A, et al. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res. 2012;37:684–688.
   PubMed Web of Science ®Google Scholar
• Celebi AR, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol. 2014;252:619–626.
   PubMed Web of Science ®Google Scholar
• Jirsova K, Brejchova K, Krabcova I, et al. The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment. Curr Eye Res. 2014;39:21–30.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hirayama M, Cui X, et al. Effectiveness of autologous serum eye drops combined with punctal plugs for the treatment of Sjögren Syndrome-related dry eye. Cornea. 2015;34(10):1214–1220.
   PubMed Web of Science ®Google Scholar
• Mondy P, Brama T, Fisher J, et al. Sustained benefits of autologous serum eye drops on self-reported ocular symptoms and vision-related quality of life in Australian patients with dry eye and corneal epithelial defects. Transfus Apher Sci. 2015;53(3):404–411.
   PubMed Web of Science ®Google Scholar
• Von Hofsten J, Egardt M, Zetterberg M. The use of autologous serum for the treatment of ocular surface disease at a Swedish tertiary referral center. Int Med Case Rep J. 2016;9:47–54.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Okamoto S, Mori T, et al. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea. 2007;26:861–863.
   PubMed Web of Science ®Google Scholar
• Na KS, Kim MS. Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther. 2012;28(5):479–483.
   PubMed Web of Science ®Google Scholar
• Harritshoj LH, Nielsen C, Ullum H, et al. Ready-made allogeneic ABO specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy. Acta Ophthalmol. 2014;92:783–786.
   PubMed Web of Science ®Google Scholar
• Yoon KC, Im SK, Park YG, et al. Application of umbilical cord serum eyedrops for the treatment of dry eye syndrome. Cornea. 2006;25(3):268–272.
   PubMed Web of Science ®Google Scholar
• Yoon KC, Jeong IY, Im SK, et al. Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease. Bone Marrow Transplant. 2007;39:231–235.
   PubMed Web of Science ®Google Scholar
• Yoon KC, Heo H, Im SK, et al. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol. 2007 Jul;144(1):86–92.
   PubMed Web of Science ®Google Scholar
• Versura P, Profazio V, Buzzi M, et al. Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea. 2013;32:412–418.
   PubMed Web of Science ®Google Scholar
• Yoon KC, Oh HJ, Park JW, et al. Application of umbilical cord serum eyedrops after laser epithelial keratomileusis. Acta Ophthalmol. 2013;91:e22–e28.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Sen S, Datta H. Comparative role of 20% cord blood serum and 20% autologous serum in dry eye associated with Hansen’s disease: a tear proteomic study. Br J Ophthalmol. 2015;99(1):108–112.
   PubMed Web of Science ®Google Scholar
• Alio JL, Colecha JR, Pastor S, et al. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res. 2007;39(3):124–129.
   PubMed Web of Science ®Google Scholar
• Avila MY. Restoration of human lacrimal function following platelet-rich plasma injection. Cornea. 2014;33(1):18–21.
   PubMed Web of Science ®Google Scholar
• López-Plandolit S, Morales MC, Freire V, et al. Efficacy of plasma rich in growth factors for the treatment of dry eye. Cornea. 2011;30(12):1312–1317.
   PubMed Web of Science ®Google Scholar
• Pezzotta S, Del Fante C, Scudeller L, et al. Autologous platelet lysate for treatment of refractory ocular GVHD. Bone Marrow Transplant. 2012;47(12):1558–1563.
   PubMed Web of Science ®Google Scholar
• Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, et al. Safety and efficacy of autologous plasma rich in growth factors eye drops for the treatment of evaporative dry eye. Ophthalmic Res. 2016;56(2):68–73.
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Martel JR, Sall K, et al. Multicenter study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in subjects with moderate to severe dry eye disease. Eye Contact Lens. 2016 Jul 27. DOI: 10.1097/ICL.0000000000000276. [Epub ahead of print].
   PubMedGoogle Scholar
• Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275–1285.
   PubMedGoogle Scholar
• Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016 Feb 23;2:CD009729.
   PubMed Web of Science ®Google Scholar
• Simmons PA, Liu H, Carlisle-Wilcox C, et al. Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial. Clin Ophthalmol. 2015;9:665–675.
   PubMed Web of Science ®Google Scholar
• Torkildsen G. The effects of lubricant eye drops on visual function as measured by the Inter-blink interval Visual Acuity Decay test. Clin Ophthalmol. 2009;3:501–506.
   PubMedGoogle Scholar
• Hall JQ Jr., Ridder WH 3rd, Nguyen AL, et al. Visual effect and residence time of artificial tears in dry eye subjects. Optom Vis Sci. 2011;88(7):872–880.
   PubMed Web of Science ®Google Scholar
• McGinnigle S, Eperjesi F, Naroo SA. A preliminary investigation into the effects of ocular lubricants on higher order aberrations in normal and dry eye subjects. Cont Lens Anterior Eye. 2014;37(2):106–110.
   PubMed Web of Science ®Google Scholar
• Calonge M, Enríquez-de-Salamanca A, Diebold Y, et al. Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm. 2010 Aug;18(4):244–253.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Comstock TL, Cavet ME. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on intraocular pressure. Adv Ther. 2016 Apr;33(4):532–552.
   PubMed Web of Science ®Google Scholar
• Bielory BP, Shah SP, O’Brien TP, et al. Emerging therapeutics for ocular surface disease. Curr Opin Allergy Clin Immunol. 2016;16(5):477–486.
   PubMed Web of Science ®Google Scholar
• Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med. 2000 Jun 21;2(4):1–23.
   PubMedGoogle Scholar
• Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118(11):1489–1496.
   PubMedGoogle Scholar
• Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci. 2001;42(1):90–95.
   PubMed Web of Science ®Google Scholar
• Di Tommaso C, Valamanesh F, Miller F, et al. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. Invest Ophthalmol Vis Sci. 2012;53(4):2292–2299.
   PubMed Web of Science ®Google Scholar
• Khan W, Aldouby YH, Avramoff A, et al. Cyclosporin nanosphere formulation for ophthalmic administration. Int J Pharm. 2012 Nov 1;437(1–2):275–276.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Aller M, Kaufmann B, Guillarme D, et al. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. Eur J Pharm Biopharm. 2012;80(3):544–552.
   PubMed Web of Science ®Google Scholar
• Barachetti L, Rampazzo A, Mortellaro CM, et al. Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study. Vet Ophthalmol. 2015;18(3):234–241.
   PubMed Web of Science ®Google Scholar
• Kim H, Csaky KG, Gilger BC, et al. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):655–662.
   PubMed Web of Science ®Google Scholar
• Peng CC, Chauhan A. Extended cyclosporine delivery by silicone-hydrogel contact lenses. J Control Release. 2011;154(3):267–274.
   PubMed Web of Science ®Google Scholar
• Tong L, Wong TY. Aspirin and dry eye? Ophthalmology. 2009;116(1):167–167.e1.
   PubMed Web of Science ®Google Scholar
• Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;7:CD009864.
   PubMedGoogle Scholar
• Fujita E, Teramura Y, Shiraga T, et al. Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. J Ocul Pharmacol Ther. 2008;24(3):309–319.
   PubMed Web of Science ®Google Scholar
• Aoki S, Mizote H, Minamoto A, et al. Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease. Br J Ophthalmol. 2005;89(2):243–244.
   PubMed Web of Science ®Google Scholar
• Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2):207–215.
   PubMed Web of Science ®Google Scholar
• Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083–1094.
   PubMed Web of Science ®Google Scholar
• Paskowitz DM, Nguyen QD, Gehlbach P, et al. Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study. Eye (Lond). 2012;26(7):944–949.
   PubMed Web of Science ®Google Scholar
• Zhong M, Gadek TR, Bui M, et al. Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012;3(3):203–206.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Whitley WO, Sall K, et al. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials. Curr Med Res Opin. 2016 Jul;22:1–7.
   Google Scholar
• Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of Lifitegrast Ophthalmic Solution 5.0% in patients with dry eye disease: A 1-Year, multicenter, randomized, placebo-controlled study. Cornea. 2016 Jun;35(6):741–748.
   PubMed Web of Science ®Google Scholar
• Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010;7:41.
   Google Scholar
• Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib -an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016 Mar–Apr;34(2):318–328.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–4243.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64(3):617–629.
   PubMed Web of Science ®Google Scholar
• Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129(9):2299–2302.
   PubMed Web of Science ®Google Scholar
• Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009;9(8):1936–1945.
   PubMed Web of Science ®Google Scholar
• Frucht-Pery J, Chayet AS, Feldman ST, et al. The effect of doxycycline on ocular rosacea. Am J Ophthalmol. 1989;107(4):434–435.
   PubMed Web of Science ®Google Scholar
• Aronowicz JD, Shine WE, Oral D, et al. Short term oral minocycline treatment of meibomianitis. Br J Ophthalmol. 2006;90(7):856–860.
   PubMed Web of Science ®Google Scholar
• Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res. 2003;76(4):417–420.
   PubMed Web of Science ®Google Scholar
• Vincent S, Bronze MS, Cooper TW, et al. Tetracycline and glycylcycline antimicrobials. J Okla State Med Assoc. 2007;100(6):241–247.
   PubMedGoogle Scholar
• De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006;47:2847–2856.
   PubMed Web of Science ®Google Scholar
• Gough A, Chapman S, Wagstaff K, et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Bmj. 1996;312:169–172.
   PubMed Web of Science ®Google Scholar
• Parneix-Spake A, Bastuji-Garin S, Lobut JB, et al. Minocycline as possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol. 1995;131:490–491.
   PubMedGoogle Scholar
• Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7:S1–S14.
   PubMed Web of Science ®Google Scholar
• Pechère JC. Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity [in French]. Pathol Biol (Paris). 1995;43:483–487.
   PubMed Web of Science ®Google Scholar
• Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother. 1998;41(suppl B):47–50.
   PubMedGoogle Scholar
• Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010 Jul;23(3):590–615.
   PubMed Web of Science ®Google Scholar
• Liu Y, Kam WR, Ding J, et al. Effect of azithromycin on lipid accumulation in immortalized human meibomian gland epithelial cells. JAMA Ophthalmol. 2014;132:226–228.
   PubMed Web of Science ®Google Scholar
• Liu Y, Kam WR, Ding J, et al. One man’s poison is another man’s meat: using azithromycin-induced phospholipidosis to promote ocular surface health. Toxicology. 2014;320:1–5.
   PubMed Web of Science ®Google Scholar
• Liu Y, Kam WR, Ding J, et al. Can tetracycline antibiotics duplicate the ability of azithromycin to stimulate human meibomian gland epithelial cell differentiation? Cornea. 2015;34(3):342–346.
   PubMed Web of Science ®Google Scholar
• Samarawickrama C, Chew S, Watson S. PMID:25890622. Retinoic acid and the ocular surface. Surv Ophthalmol. 2015;60:183–195.
   PubMed Web of Science ®Google Scholar
• Tseng SC. Topical tretinoin treatment for severe dry-eye disorders. J Am Acad Dermatol. 1986;15:860–866.
   PubMed Web of Science ®Google Scholar
• Driot JY, Bonne C. Beneficial effects of a retinoic acid analog, CBS-211 A, on an experimental model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 1992;33:190–195.
   PubMed Web of Science ®Google Scholar
• Kruk J, Kubasik-Kladna K, Aboul-Enein HY. The role oxidative stress in the pathogenesis of eye diseases: current status and a dual role of physical activity. Mini Rev Med Chem. 2015;16(3):241–257.
   PubMed Web of Science ®Google Scholar
• Roncone M, Bartlett H, Eperjesi F, Essential fatty acids for dry eye: A review. Cont Lens Anterior Eye. 2010;332:49–54. quiz 100
   PubMed Web of Science ®Google Scholar
• Hom MM, Asbell P, Barry B. Omegas and dry eye: more knowledge, more questions. Optom Vis Sci. 2015;92(9):948–956.
   PubMed Web of Science ®Google Scholar
• Cortina MS, Bazan HE. Docosahexaenoic acid, protectins and dry eye. Curr Opin Clin Nutr Metab Care. 2011;14(2):132–137.
   PubMed Web of Science ®Google Scholar
• Järvinen RL, Larmo PS, Setälä NL, et al. Effects of oral sea buckthorn oil on tear film Fatty acids in individuals with dry eye. Cornea. 2011 Sep;30(9):1013–1019.
   PubMed Web of Science ®Google Scholar
• Li N, He J, Schwartz CE, et al. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther. 2010;26:431–439.
   PubMed Web of Science ®Google Scholar
• Rashid S, Jin Y, Ecoiffier T, et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126(2):219–225.
   PubMedGoogle Scholar
• Li Z, Choi JH, Oh HJ, et al. Effects of eye drops containing a mixture of omega-3 essential fatty acids and hyaluronic acid on the ocular surface in desiccating stress-induced murine dry eye. Curr Eye Res. 2014;39(9):871–888.
   PubMed Web of Science ®Google Scholar
• McCusker MM, Durrani K, Payette MJ, et al. An eye on nutrition: the role of vitamins, essential fatty acids, and antioxidants in age-related macular degeneration, dry eye syndrome, and cataract. Clin Dermatol. 2016;34(2):276–285.
   PubMed Web of Science ®Google Scholar
• Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015;13(2):118–132.
   PubMed Web of Science ®Google Scholar
• Brasky TM, Darke AK, Song X, et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013;105(15):1132–1141.
   PubMed Web of Science ®Google Scholar
• Aucoin M, Cooley K, Knee C, et al. Fish-derived Omega-3 Fatty Acids and prostate cancer: a systematic review. Integr Cancer Ther. 2016Jun29. pii: 1534735416656052
   PubMed Web of Science ®Google Scholar
• Nakatsukasa M, Sotozono C, Shimbo K, et al. Amino Acid profiles in human tear fluids analyzed by high-performance liquid chromatography and electrospray ionization tandem mass spectrometry. Am J Ophthalmol. 2011;151(5):799–808.e1.
   PubMed Web of Science ®Google Scholar
• Rusciano D, Roszkowska AM, Gagliano C, et al. Free amino acids: an innovative treatment for ocular surface disease. Eur J Pharmacol. 2016;787:9–19.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Rao K, Pflugfelder SC. Corneal epithelial opacity in dysfunctional tear syndrome. Am J Ophthalmol. 2009;148:376–382.
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002;966:211–222.
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Wickham LA, Rocha EM, et al. Androgens and dry eye in Sjögren’s syndrome. Ann N Y Acad Sci. 1999;876:312–324.
   PubMed Web of Science ®Google Scholar
• Feng Y, Feng G, Peng S, et al. The effect of hormone replacement therapy on dry eye syndrome evaluated with schirmer test and break-up time. J Ophthalmol. 2015;2015:420302.
   PubMed Web of Science ®Google Scholar
• Truong S, Cole N, Stapleton F, et al. Sex hormones and the dry eye. Clin Exp Optom. 2014;97(4):324–336.
   PubMed Web of Science ®Google Scholar
• Lemp MA. Management of Dry Eye Disease. Am J Manag Care. 2008;14:S88–S101.
   PubMed Web of Science ®Google Scholar
• Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol. 2013;7:1797–1803.
   PubMedGoogle Scholar
• Thode AR, Latkany RA. Current and emerging therapeutic strategies for the treatment of Meibomian Gland Dysfunction (MGD). Drugs. 2015;75(11):1177–1185.
   PubMed Web of Science ®Google Scholar
• Ciurtin C, Ostas A, Cojocaru VM, et al. Advances in the treatment of ocular dryness associated with Sjögren׳s syndrome. Semin Arthritis Rheum. 2015;45(3):321–327.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Lindsley KB, Adyanthaya RS, et al. Treatment of Sjögren’s syndrome-associated dry eye an evidence-based review. Ophthalmology. 2011;118(7):1242–1252.
   PubMed Web of Science ®Google Scholar
• Nichols KK, Yerxa B, Kellerman DJ. Diquafosol tetrasodium: a novel dry eye therapy. Expert Opin Investig Drugs. 2004;13(1):47–54.
   PubMed Web of Science ®Google Scholar
• Kashima T, Itakura H, Akiyama H, et al. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal. Clin Ophthalmol. 2014;8:1003–1010.
   PubMedGoogle Scholar
• Tanaka H, Fukuda K, Ishida W, et al. Rebamipide increases barrier function and attenuates TNFα-induced barrier disruption and cytokine expression in human corneal epithelial cells. Br J Ophthalmol. 2013;97(7):912–916.
   PubMed Web of Science ®Google Scholar
• Itoh S, Itoh K, Shinohara H. Regulation of human corneal epithelial mucins by rebamipide. Curr Eye Res. 2014;39(2):133–141.
   PubMed Web of Science ®Google Scholar
• Takeji Y, Urashima H, Aoki A, et al. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012;28(3):259–263.
   PubMed Web of Science ®Google Scholar
• Yamane M, Ogawa Y, Fukui M, et al. Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye. Optom Vis Sci. 2015 Apr;92(4 Suppl 1):S25–32.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kamiya K, Kobashi H, et al. Effect of rebamipide ophthalmic suspension on intraocular light scattering for dry eye after corneal refractive surgery. Cornea. 2015;34(8):895–900.
   PubMed Web of Science ®Google Scholar
• Machida Y, Shoji J, Harada N, et al. Two patients with dry eye disease followed up using an expression assay of ocular surface mucin. Case Rep Ophthalmol. 2016;7(1):208–215.
   PubMed Web of Science ®Google Scholar
• Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol. 2016;100(1):22–27.
   PubMed Web of Science ®Google Scholar
• van der Meer PF, Seghatchian J, Marks DC, et al. Quality standards, safety and efficacy of blood-derived serum eye drops: A review. Transfus Apher Sci. 2016;54(1):164–167.
   PubMed Web of Science ®Google Scholar
• Liu L, Hartwig D, Harloff S, et al. Corneal epitheliotrophic capacity of three different blood-derived preparations. Invest Ophthalmol Vis Sci. 2006;47(6):2438–2444.
   PubMed Web of Science ®Google Scholar
• Freire V, Andollo N, Etxebarria J, et al. In vitro effects of three blood derivatives on human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2012;53(9):5571–5578.
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzabal F, Tayebba A, et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015;93(8):e605–614.
   PubMed Web of Science ®Google Scholar
• Azari AA, Rapuano CJ. Autologous serum eye drops for the treatment of ocular surface disease. Eye Contact Lens. 2015;41(3):133–140.
   PubMed Web of Science ®Google Scholar
• Kojima T, Higuchi A, Goto E, et al. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008;27(Suppl 1):S25–30.
   PubMed Web of Science ®Google Scholar
• Poon AC, Geerling G, Dart JK, et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001;85:1188–1197.
   PubMed Web of Science ®Google Scholar
• Katsakoulas I, Lougovoi C, Paraskevopoulou P, et al. Protocol of blood serum eye drops. Int J Pharm Compd. 2015;19(3):252–260.
   PubMedGoogle Scholar
• Mixon B, Mixon J, Isbey EK 3rd, et al. Autologous serum eye drops for severe dry eye syndrome in a patient with chronic graft-versus-host disease: a case report. Int J Pharm Compd. 2014;18(5):370–377.
   PubMedGoogle Scholar
• Yoon KC. Use of umbilical cord serum in ophthalmology. Chonnam Med J. 2014 Dec;50(3):82–85.
   PubMedGoogle Scholar
• Alio JL, Rodriguez AE, WróbelDudzińska D. Eye platelet-rich plasma in the treatment of ocular surface disorders. Curr Opin Ophthalmol. 2015;26(4):325–332.
   PubMed Web of Science ®Google Scholar
• Eberle J, Habermann J, Gürtler LG. HIV-1 infection transmitted by serum droplets into the eye: a case report. Aids. 2000;14(2):206–207.
   PubMed Web of Science ®Google Scholar
• Seghatchian J, Espinosa A, Burnouf T. Quality, safety and sustained therapeutic efficacy of blood-derived serum eye drops to treat dry eye syndrome: R&D road map for future progress. Transfus Apher Sci. 2016;54(1):168–169.
   PubMed Web of Science ®Google Scholar
• Maliartchouk S, Feng Y, Ivanisevic L, et al. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol Pharmacol. 2000;57(2):385–391.
   PubMed Web of Science ®Google Scholar
• Jain P, Li R, Saragovi HU, et al. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secre- tion and demonstrates therapeutic efficacy in a rate model in dry eye. Exp Eye Res. 2011;93(4):503–512.
   PubMed Web of Science ®Google Scholar
• Management and therapy of dry eye disease: report of the management and therapy subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5(2):163–178.
   PubMed Web of Science ®Google Scholar